Imaging costs were front and center in an investigative review of Sutter Health pricing practices conducted by Bloomberg News.
Imaging costs were front and center in an investigative review of Sutter Health pricing practices conducted by Bloomberg News.
The review, published online Aug. 19, explored how the nonprofit Sutter Healthcare system had become a dominant player in the markets it serves and, as a consequence, had the power to set prices that were often much higher than those charged by competitors.
Imaging costs were among the examples:
The article quoted insurance executives for Aetna, Health Net, and Blue Shield of California as saying Sutter can charge higher prices because it has acquired more than a third of the market in the San Francisco-to-Sacramento region through more than 20 hospital takeovers. The executives asked not to be named because their agreements with Sutter ban disclosure of prices, the article said.
Sutter’s chief executive officer Patrick Fry defended the network, saying Sutter Health doesn’t have market power, given the choices that employers can make.
Federal investigators in five states-Connecticut, Massachusetts, Ohio, Pennsylvania, and New Hampshire-are probing proposed hospital takeovers or contracting practices for evidence of antitrust problems, Bloomberg reported. A Sutter spokesman said it knows of no federal or state antitrust investigations into its conduct.
FDA Clears Enhanced MRI-Guided Laser Ablation System
June 5th 2025An alternative to an open neurosurgical approach, the Visualase V2 MRI-Guided Laser Ablation System reportedly utilizes laser interstitial thermal therapy (LITT) for targeted soft tissue ablation in patients with brain tumors and focal epilepsy.
Can Abbreviated MRI Have an Impact in Differentiating Intraductal Papilloma and Ductal Secretion?
June 3rd 2025For patients with inconclusive ultrasound results, abbreviated breast MRI offers comparable detection of intraductal papilloma as a full breast MRI protocol at significantly reduced times for scan acquisition and interpretation, according to a new study.
Can AI Assessment of PET Imaging Predict Treatment Outcomes for Patients with Lymphoma?
June 2nd 2025The use of adjunctive AI software with pre-treatment PET imaging demonstrated over a fourfold higher likelihood of predicting progression-free survival (PFS) in patients being treated for lymphoma, according to a new meta-analysis.